Identification of novel somatic fusions of ERG-VEGFA, TMPRSS2-ERG , and VEGFA-TMPRSS2 in prostate cancer treated with anlotinib and androgen deprivation therapy: A case report.
Qiuli LiuShuo WangZe WangPeng TangDianzheng ZhangWeihua LanJun JiangPublished in: Cancer innovation (2022)
The TMPRSS2-ERG fusion gene has frequently been found in prostate cancer and is associated with malignancy. Identifying novel fusions will help to stratify patients and establish patient-tailored therapies. A 78-year-old man presented to our hospital with severe symptoms of urinary urgency and frequency for 2 years, as well as severe bone pain for 1 year. He was diagnosed with metastatic prostate cancer with a Gleason score of 5 + 5. Three gene fusions, ERG_VEGFA , TMPRSS2_ERG , and VEGFA_TMPRSS2 , were identified in the patient's prostate cancer tissue. Notably, administration of the tyrosine kinase inhibitor, anlotinib, in combination with a gonadotropin-releasing hormone agonist (GnRHa) and abiraterone, reduced the patient's bone pain and also stabilized his prostate cancer for more than 2 years. This is the first report of somatic fusions among the VEGFA , ERG , and TMPRSS2 genes in cancer tissues from a patient with prostate cancer who responded well to antiangiogenic treatment combined with a GnRHa and abiraterone.
Keyphrases
- prostate cancer
- radical prostatectomy
- case report
- chronic pain
- copy number
- small cell lung cancer
- gene expression
- newly diagnosed
- healthcare
- genome wide
- neuropathic pain
- squamous cell carcinoma
- young adults
- physical activity
- spinal cord
- emergency department
- end stage renal disease
- bone mineral density
- replacement therapy
- stem cells
- postmenopausal women
- postoperative pain
- early onset
- squamous cell
- genome wide identification
- genome wide analysis
- smoking cessation